• Home/
  • Guiding the Global Evolution of Cytogenetic Testing for Hematologic Malignancies.

Guiding the Global Evolution of Cytogenetic Testing for Hematologic Malignancies.

Blood 2022
Akkari Y, et al.

Yassmine M. N. Akkari, Linda B. Baughn, Adrian M Dubuc, Adam C Smith, Mar Mallo, Paola Dal Cin, María Díez-Campelo, Marta S Gallego, Isabel Granada, Detlef Thomas Haase, Brigitte Schlegelberger, Irma Slavutsky, Cristina Mecucci, Ross L. Levine, Robert P Hasserjian, Francesc Sole, Brynn Levy, Xinjie Xu.

Cytogenetics has long represented a critical component in the clinical evaluation of hematologic malignancies. Chromosome banding studies provide a simultaneous snapshot of genome-wide copy number and structural variation, which have been shown to drive tumorigenesis, define diseases, and guide treatment. Technological innovations in sequencing have ushered in our present-day clinical genomics era. With recent publications highlighting novel sequencing technologies as alternatives to conventional cytogenetic approaches, we, an international consortium of laboratory geneticists, pathologists and oncologists, describe herein the advantages and limitations of both conventional chromosome banding and novel sequencing technologies, and share our considerations on crucial next steps to implement these novel technologies in the global clinical setting for a more accurate cytogenetic evaluation, which may provide improved diagnosis and treatment management. Considering the clinical, technical, and economic implications, we provide points to consider for the global evolution of cytogenetic testing.


This website stores cookies on your computer. These cookies are used to collect information about how you interact with our website and allow us to remember you. We use this information in order to improve and customize your browsing experience and for analytics and metrics about our visitors both on this website and other media. To find out more about the cookies we use, see our Privacy Policy.